Institute for Advanced Research, Wenzhou Medical University
Opportunities for Inaugural Institute Principal Investigators and Professors
The Wenzhou Medical University Institute for Advanced Research (WMU-IFAR) is recruiting for an inaugural team of exceptional world-class and impact-oriented Principal Investigators. WMU-IFAR is located in the coastal city of Wenzhou in coastal Southeast China. It is a brand-new life sciences research institute founded by Wenzhou Medical University in collaboration with the globally highly ranked University of Queensland. IFAR has been designed with a clear vision to make major impact in the betterment of human life. Wenzhou Medical University, along with its five affiliated hospitals (four of which are ranked as Grade 3 Class A) and 19 non-directly affiliated teaching hospitals, has an established and undisputed reputation for being an epicenter for healthcare in China, combining research, education and medical services.
With a focus on diversity and the value of people, the Institute will provide a vibrant, well-supported working environment. It will be equipped with state-of-the-art research facilities purpose-built for research, training, and outcome commercialization. Led by Director Prof. Jian Yang, the Institute will conduct cutting-edge research focused on (but not limited to) five key research themes:
1) Data science and public health
2) Cancer and immunotherapy
3) Genomics and novel sequencing technologies
4) Functional genomics and model systems
5) Stem cell and nanomedicine.
Professor and Group Leader (up to 10 positions available). Positions will be broad-banded across three levels (based on experience): Principal Investigator/Senior Principal Investigator/Distinguished Principal Investigator.
All Institute Group Leaders will be appointed at the level of Professor.
As a WMU-IFAR Professor and Group Leader, you will develop a productive independent research program, funded by a generous start-up package from WMU-IFAR as well as competitive grants and fellowships. You will conduct world-leading science, develop strong multidisciplinary national and international collaborations, and actively promote translation of research outcomes to medicine or technology. You will be viewed particularly favorably if you have an interest in cutting-edge technologies that address fundamental questions in human health.
We are currently inviting applications for highly qualified research innovators who are passionate about making a difference in advancing human health and who are active and motivated in training future research leaders. To be successful in this role, candidates will be international research leaders in life sciences (evidenced by citation rate, highly cited papers, conference presentations, awards and achievements). They will be driven towards excellence and innovation in research with a desire to advance the field. Successful candidates will also have a track record that demonstrates success in winning competitive research funding and forming successful and productive international collaborations. Experience in commercialization and research translation is highly advantageous.
Salary and Research Support Packages:
Salary package: Group Leaders will receive an annual salary of 600K to 1.2M RMB (plus publication bonus and negotiable market loadings), depending on experience and level of appointment. Relocation allowance of 300K to 500K RMB, and housing subsidies of 1.5 to 2.1M RMB will be available to successful candidates.
Research support package: Start-up research funding of 5M to 10M RMB will be awarded to all successful Group Leaders. Additional funding will also be provided to cover full salaries of a number of staff members, depending on the Group Leader’s appointment level. An additional 1M RMB in lab funding will be awarded if a Postdoc receives an Excellence in Research Award.
WMU-IFAR is committed to equity and diversity, including gender equity, in its recruitment activities.
The first batch of applicants will be invited for interview in December 2018, followed by another possible round of interview in April 2019.